<!DOCTYPE html>
<html lang="en">
<head>

<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">

<title>Human Kratom Studies | FDA Clinical Trial and Pharmacokinetic Data</title>

<meta name="description" content="Structured review of FDA-registered human kratom studies, including clinical trial NCT06072170 and controlled pharmacokinetic evaluations of mitragynine and 7-hydroxymitragynine.">

<meta name="keywords" content="kratom human study, NCT06072170, mitragynine clinical trial, 7-hydroxymitragynine metabolism, kratom drug liking, FDA kratom study">

<meta name="author" content="Kratom Regulatory Review">
<meta name="theme-color" content="#0c2d48">

<link rel="canonical" href="https://kratomregulatoryreview.org/human-studies.html">

<!-- Open Graph -->
<meta property="og:title" content="Human Kratom Studies | FDA Clinical Trial Data">
<meta property="og:description" content="Regulatory review of controlled human kratom studies including pharmacokinetics, 7-OH formation, and drug-liking findings.">
<meta property="og:type" content="website">
<meta property="og:url" content="https://kratomregulatoryreview.org/human-studies.html">

<!-- Google Analytics -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-MQKC65VZVY"></script>
<script async src="https://www.googletagmanager.com/gtag/js?id=G-P31PD1SSTD"></script>
<script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config','G-MQKC65VZVY');
gtag('config','G-P31PD1SSTD');
</script>

<link rel="stylesheet" href="css/style.css">

<style>
.page-header { padding: 40px 0 25px 0; }
.page-intro { max-width: 900px; margin-bottom: 14px; line-height: 1.7; }
.section { padding: 40px 0; }
.alt-bg { background:#f9fafb; }
.card { border:1px solid #e2e8f0; border-radius:12px; padding:20px; background:#fff; margin-bottom:22px; }
.card h3 { margin-top:0; }
.note { font-size:14px; color:#4b5563; line-height:1.6; }
.footer { background:#0c2d48; color:#fff; padding:30px 0; text-align:center; margin-top:40px; }
</style>

</head>
<body>

<div class="gov-banner">
üá∫üá∏ Informational public health resource. Educational reference for legislative and regulatory review.
</div>

<header class="site-header">
  <div class="container header-inner">
    <div class="site-title">Kratom Regulatory Review</div>
  </div>
</header>

<nav class="main-nav">
  <div class="container nav-inner">
    <a href="index.html">Overview</a>
    <a href="mortality.html">Mortality</a>
    <a href="adverse.html">Adverse Events</a>
    <a href="poison.html">Poison Control</a>
    <a href="KratomCaseReports.html">Case Reports</a>
    <a href="human-studies.html" class="active">Human Studies</a>
  </div>
</nav>

<section class="page-header">
  <div class="container">
    <h1>Human Kratom Studies</h1>

    <p class="page-intro">
      This page summarizes controlled human studies evaluating kratom (Mitragyna speciosa)
      and its primary alkaloids, mitragynine and 7-hydroxymitragynine (7-OH).
    </p>

    <p class="page-intro">
      Included are one FDA-registered clinical research result and peer-reviewed pharmacokinetic
      investigations examining safety, metabolism, subjective effects, and dose response
      under controlled laboratory conditions.
    </p>

  </div>
</section>
 <section class="section">
  <div class="container">

    <!-- STUDY 1: HUESTIS 2026 SAFETY/TRIAL -->
    <div class="card">
      <h3>Randomized Safety & Tolerability Trial (Huestis et al., 2026)</h3>

      <p>
        This was a controlled clinical study in healthy adults designed to evaluate
        short-term safety and side effects of dried kratom leaf powder compared with placebo.
        Participants received single doses and then 15 daily doses in a supervised setting.  [oai_citation:0‚Ä°Huestis study 2026.pdf](sediment://file_00000000a93871f5a4f74b3008b814bf)
      </p>

      <h4>What was studied (plain language)</h4>
      <ul>
        <li>116 volunteers total (49 received kratom; 67 received placebo).  [oai_citation:1‚Ä°Huestis study 2026.pdf](sediment://file_00000000a93871f5a4f74b3008b814bf)</li>
        <li>Four dose levels of mitragynine (6.65, 13.3, 26.6, 53.2 mg).  [oai_citation:2‚Ä°Huestis study 2026.pdf](sediment://file_00000000a93871f5a4f74b3008b814bf)</li>
        <li>Product contained very little pre-formed 7-OH (&lt;0.01%), meaning most 7-OH exposure comes from metabolism in the body.  [oai_citation:3‚Ä°Huestis study 2026.pdf](sediment://file_00000000a93871f5a4f74b3008b814bf)</li>
      </ul>

      <h4>7-OH produced in the body</h4>
      <p>
        The paper explains that 7-hydroxymitragynine (7-OH) is primarily formed in humans
        through metabolism of mitragynine (largely via CYP3A4), rather than being present in fresh leaf.  [oai_citation:4‚Ä°Huestis study 2026.pdf](sediment://file_00000000a93871f5a4f74b3008b814bf)
      </p>

      <h4>Side effects reported</h4>
      <p>
        No deaths and no serious adverse events were reported. Side effects generally increased with higher doses.  [oai_citation:5‚Ä°Huestis study 2026.pdf](sediment://file_00000000a93871f5a4f74b3008b814bf)
      </p>
      <ul>
        <li>Most common after single dose: dizziness, nausea, feeling relaxed.  [oai_citation:6‚Ä°Huestis study 2026.pdf](sediment://file_00000000a93871f5a4f74b3008b814bf)</li>
        <li>Most common after multiple daily dosing: headache, feeling hot, elevated ALT, nausea.  [oai_citation:7‚Ä°Huestis study 2026.pdf](sediment://file_00000000a93871f5a4f74b3008b814bf)</li>
      </ul>

      <h4>Drug liking / ‚Äúhigh‚Äù</h4>
      <p>
        The study collected abuse-liability signals (including ‚Äúdrug effect‚Äù ratings) and reports that
        euphoric mood was uncommon: it was reported in only a small number of participants and was not reported
        during the multiple-dose phase in active kratom recipients.  [oai_citation:8‚Ä°Huestis study 2026.pdf](sediment://file_00000000a93871f5a4f74b3008b814bf)
      </p>

      <h4>Did anyone drop out?</h4>
      <p>
        Yes. The paper reports early terminations for suspected product-related events, including elevated liver enzymes and
        severe gastroenteritis in one case; some participants were also withdrawn at higher doses due to ALT/AST elevations that resolved after stopping dosing.  [oai_citation:9‚Ä°Huestis study 2026.pdf](sediment://file_00000000a93871f5a4f74b3008b814bf)
      </p>

      <h4>Who sponsored and who conducted it?</h4>
      <p>
        Funding disclosure in the paper states the study was paid for by NP Pharma, and authors report consultant fees from NP Pharma.
        Study product referenced: MitraLeaf (encapsulated dried kratom leaf powder).  [oai_citation:10‚Ä°Huestis study 2026.pdf](sediment://file_00000000a93871f5a4f74b3008b814bf)
      </p>

      <p>
        <a href="../Human_studies/Huestis%20study%202026.pdf" target="_blank">
          Open PDF: Huestis study 2026 ‚Üí
        </a>
      </p>
    </div>


    <!-- STUDY 2: HUESTIS 2024 PK -->
    <div class="card">
      <h3>Human Pharmacokinetics of Mitragynine and 7-OH (Huestis et al., 2024)</h3>

      <p>
        This study measured how mitragynine and 7-hydroxymitragynine (7-OH) appear in blood
        after single dosing and after repeated daily dosing of encapsulated dried kratom leaf powder.  [oai_citation:11‚Ä°Huestis PK 2024.pdf](sediment://file_0000000040e471f5a2324f61488d5b8b)
      </p>

      <h4>Why this matters</h4>
      <p>
        Even when the product contains extremely low 7-OH, the study demonstrates measurable 7-OH in plasma
        because the body converts mitragynine into 7-OH.  [oai_citation:12‚Ä°Huestis PK 2024.pdf](sediment://file_0000000040e471f5a2324f61488d5b8b)
      </p>

      <h4>Key findings in plain language</h4>
      <ul>
        <li>Both mitragynine and 7-OH increased with higher doses.  [oai_citation:13‚Ä°Huestis PK 2024.pdf](sediment://file_0000000040e471f5a2324f61488d5b8b)</li>
        <li>Steady-state levels were reached in about 8‚Äì9 days for mitragynine and ~7 days for 7-OH.  [oai_citation:14‚Ä°Huestis PK 2024.pdf](sediment://file_0000000040e471f5a2324f61488d5b8b)</li>
        <li>The 7-OH/mitragynine ratio was higher after single dosing and decreased somewhat after repeated dosing.  [oai_citation:15‚Ä°Huestis PK 2024.pdf](sediment://file_0000000040e471f5a2324f61488d5b8b)</li>
      </ul>

      <h4>Sponsorship and conduct</h4>
      <p>
        The paper reports that the clinical study was paid for by Johnson Foods, LLC, and conducted by SGS Nutrasource in Ontario, Canada,
        with disclosed consulting relationships.  [oai_citation:16‚Ä°Huestis PK 2024.pdf](sediment://file_0000000040e471f5a2324f61488d5b8b)
      </p>

      <p>
        <a href="../Human_studies/Huestis%20PK%202024.pdf" target="_blank">
          Open PDF: Huestis PK 2024 ‚Üí
        </a>
      </p>
    </div>


    <!-- STUDY 3: FDA-REGISTERED TRIAL (CLINICALTRIALS.GOV) -->
    <div class="card">
      <h3>FDA-Registered Human Study (ClinicalTrials.gov: NCT06072170)</h3>

      <p>
        This is an FDA-registered human study with results posted on ClinicalTrials.gov.
        It evaluated single-dose kratom administration under controlled conditions and includes
        outcomes such as measured alkaloid exposure (including 7-OH formation) and standardized
        subjective effect scales (e.g., drug liking and ‚Äúhigh‚Äù ratings).
      </p>

      <h4>Why it is relevant</h4>
      <p>
        ClinicalTrials.gov results provide a standardized view of participant-reported effects and laboratory measurements
        in a controlled setting. These results are helpful for understanding dose response and short-term tolerability
        but do not represent long-term use or real-world retail variability.
      </p>

      <p>
        <a href="https://clinicaltrials.gov/study/NCT06072170?tab=results" target="_blank">
          View Results on ClinicalTrials.gov ‚Üí
        </a>
      </p>
    </div>

  </div>
</section>
</section>
  <section class="section alt-bg">
  <div class="container">

    <div class="card">
      <h3>Summary Across Controlled Human Studies</h3>

      <p>
        Controlled human studies of kratom remain limited in number, but the studies summarized here
        provide structured information on metabolism, short-term tolerability, and measurable subjective effects
        under supervised conditions.
      </p>

      <h4>Key Findings (Plain Language)</h4>
      <ul>
        <li>
          <strong>7-hydroxymitragynine (7-OH) is produced in the body.</strong>
          Even when the kratom product contains very little 7-OH, participants still develop measurable 7-OH in blood,
          indicating metabolic conversion from mitragynine.
        </li>
        <li>
          <strong>Higher doses increase exposure.</strong>
          Both mitragynine and 7-OH blood levels rise with dose, and repeated dosing results in sustained exposure.
        </li>
        <li>
          <strong>Drug-effect ratings increase at higher doses.</strong>
          In the FDA-registered single-dose study, higher doses were associated with statistically significant increases
          in subjective ratings such as ‚Äúdrug liking‚Äù and ‚Äúfeeling high.‚Äù
        </li>
        <li>
          <strong>Short-term side effects were common and dose-related.</strong>
          Nausea, dizziness, headache, sleepiness, and similar effects were reported more often at higher doses.
        </li>
        <li>
          <strong>Some participants were withdrawn.</strong>
          Withdrawals occurred for reasons including elevated liver enzymes at higher doses and gastrointestinal intolerance.
        </li>
      </ul>

      <hr>

      <h4>What These Studies Do Not Evaluate</h4>
      <ul>
        <li>Long-term, high-frequency chronic use over months or years</li>
        <li>Adolescents and pediatric exposures</li>
        <li>Population-level incidence (how common events are in the general public)</li>
        <li>Real-world retail variability, including concentrated extracts and polydrug use</li>
        <li>Development of dependence and withdrawal under long-term daily use</li>
      </ul>

      <p class="note">
        Controlled trials are designed to measure effects under specific conditions. Surveillance systems
        (mortality, poison control, adverse event reporting) capture broader real-world patterns and are presented
        elsewhere on this site.
      </p>
    </div>

    <div class="card">
      <h3>Primary References</h3>
      <ul>
        <li>
          FDA-registered study results (ClinicalTrials.gov): 
          <a href="https://clinicaltrials.gov/study/NCT06072170?tab=results" target="_blank">NCT06072170 ‚Üí</a>
        </li>
        <li>
          Therapeutic Drug Monitoring (2026) safety/tolerability trial (PDF):
          <a href="assets/Huestis%20study%202026.pdf" target="_blank">Open PDF ‚Üí</a>
        </li>
        <li>
          Molecules (2024) pharmacokinetics study (PDF):
          <a href="assets/Huestis%20PK%202024.pdf" target="_blank">Open PDF ‚Üí</a>
        </li>
      </ul>
    </div>

  </div>
</section>

<footer class="footer">
  <div class="container">
    <p>¬© 2026 Kratom Regulatory Review</p>
  </div>
</footer>

</body>
</html>
